For help on how to get the results you want, see our search tips.
1531 results
Medicine
Shortages Remove Shortages filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Summaries of opinion Remove Summaries of opinion filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Authorisation status
Authorised Remove Authorised filter
-
List item
Human medicine European public assessment report (EPAR): Cosentyx (updated)
Secukinumab, Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Revision: 27, Authorised, Last updated: 24/06/2022 -
List item
Human medicine European public assessment report (EPAR): Imatinib Accord (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome
Date of authorisation: 30/06/2013,, Revision: 23, Authorised, Last updated: 23/06/2022
-
List item
Human medicine European public assessment report (EPAR): LysaKare (updated)
L-arginine hydrochloride, L-lysine hydrochloride, Radiation Injuries
Date of authorisation: 25/07/2019, Revision: 2, Authorised, Last updated: 23/06/2022 -
List item
Human medicine European public assessment report (EPAR): Erleada (updated)
apalutamide, Prostatic Neoplasms
Date of authorisation: 14/01/2019,, Revision: 7, Authorised, Last updated: 23/06/2022
-
List item
Human medicine European public assessment report (EPAR): Clopidogrel Zentiva (previously Clopidogrel Winthrop) (updated)
clopidogrel, Stroke; Peripheral Vascular Diseases; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 15/07/2008, Revision: 31, Authorised, Last updated: 23/06/2022 -
List item
Human medicine European public assessment report (EPAR): Ganfort (updated)
bimatoprost, timolol, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 19/05/2006, Revision: 22, Authorised, Last updated: 23/06/2022 -
List item
Human medicine European public assessment report (EPAR): Myfenax (updated)
mycophenolate mofetil, Graft Rejection
Date of authorisation: 21/02/2008,, Revision: 26, Authorised, Last updated: 23/06/2022
-
List item
Human medicine European public assessment report (EPAR): Lunsumio (updated)
mosunetuzumab, Lymphoma, Follicular
Date of authorisation: 03/06/2022,,
,
, Authorised, Last updated: 23/06/2022
-
List item
Human medicine European public assessment report (EPAR): Constella (updated)
linaclotide, Irritable Bowel Syndrome
Date of authorisation: 26/11/2012, Revision: 22, Authorised, Last updated: 23/06/2022 -
List item
Human medicine European public assessment report (EPAR): Erivedge (updated)
vismodegib, Carcinoma, Basal Cell
Date of authorisation: 12/07/2013,
Date of refusal: 26/04/2013, Revision: 14, Authorised, Last updated: 22/06/2022 -
List item
Human medicine European public assessment report (EPAR): Evrysdi (updated)
Risdiplam, Muscular Atrophy, Spinal
Date of authorisation: 26/03/2021,,
, Revision: 2, Authorised, Last updated: 22/06/2022
-
List item
Human medicine European public assessment report (EPAR): Givlaari (updated)
Givosiran, Porphyrias, Hepatic
Date of authorisation: 02/03/2020,,
, Revision: 4, Authorised, Last updated: 22/06/2022
-
List item
Human medicine European public assessment report (EPAR): Zejula (updated)
Niraparib (tosilate monohydrate), Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
Date of authorisation: 16/11/2017,,
, Revision: 17, Authorised, Last updated: 22/06/2022
-
List item
Human medicine European public assessment report (EPAR): Ryeqo (updated)
relugolix, norethisterone acetate, estradiol hemihydrate, Leiomyoma
Date of authorisation: 16/07/2021,, Revision: 3, Authorised, Last updated: 22/06/2022
-
List item
Human medicine European public assessment report (EPAR): Revatio (updated)
sildenafil, Hypertension, Pulmonary
Date of authorisation: 28/10/2005, Revision: 47, Authorised, Last updated: 21/06/2022 -
List item
Human medicine European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan (updated)
sitagliptin hydrochloride monohydrate, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 16/02/2022,, Revision: 1, Authorised, Last updated: 21/06/2022
-
List item
Human medicine European public assessment report (EPAR): Opsumit (updated)
Macitentan, Hypertension, Pulmonary
Date of authorisation: 20/12/2013,, Revision: 20, Authorised, Last updated: 21/06/2022
-
List item
Human medicine European public assessment report (EPAR): Kanuma (updated)
sebelipase alfa, Lipid Metabolism, Inborn Errors
Date of authorisation: 28/08/2015,,
,
, Revision: 8, Authorised, Last updated: 21/06/2022
-
List item
Human medicine European public assessment report (EPAR): Adcetris (updated)
Brentuximab vedotin, Lymphoma, Non-Hodgkin; Hodgkin Disease
Date of authorisation: 25/10/2012,,
, Revision: 33, Authorised, Last updated: 21/06/2022
-
List item
Human medicine European public assessment report (EPAR): Torisel (updated)
Temsirolimus, Carcinoma, Renal Cell; Lymphoma, Mantle-Cell
Date of authorisation: 19/11/2007, Revision: 33, Authorised, Last updated: 21/06/2022 -
List item
Human medicine European public assessment report (EPAR): Jardiance (updated)
empagliflozin, Diabetes Mellitus, Type 2
Date of authorisation: 22/05/2014, Revision: 25, Authorised, Last updated: 20/06/2022 -
List item
Human medicine European public assessment report (EPAR): Maviret (updated)
glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017,,
, Revision: 16, Authorised, Last updated: 20/06/2022
-
List item
Human medicine European public assessment report (EPAR): Ozurdex (updated)
dexamethasone, Macular Edema; Uveitis
Date of authorisation: 26/07/2010, Revision: 17, Authorised, Last updated: 17/06/2022 -
List item
Human medicine European public assessment report (EPAR): Carvykti (updated)
ciltacabtagene autoleucel, Multiple Myeloma
Date of authorisation: 25/05/2022,,
,
, Authorised, Last updated: 17/06/2022
-
List item
Human medicine European public assessment report (EPAR): Dimethyl fumarate Polpharma (updated)
dimethyl fumarate, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/05/2022,, Revision: 01, Authorised, Last updated: 17/06/2022